Picard Medical, Inc. announces the presentation of in vitro data on the fully implantable Emperor Total Artificial Heart at the ISMCS 2025.
The Emperor Total Artificial Heart is a next-generation, fully implantable total artificial heart that aims to improve patient mobility and quality of life.
The presentation at ISMCS 2025 will showcase benchtop performance data of the Emperor Total Artificial Heart platform.
Innovation in Artificial Heart Technology
The Emperor Total Artificial Heart eliminates the need for an external pneumatic driver, enhancing patient mobility.
Industry Recognition
Picard Medical will present at ISMCS 2025, a global congress for mechanical circulatory support, highlighting the significance of the Emperor Total Artificial Heart.
Commercial Success
The SynCardia Total Artificial Heart is the only commercially available artificial heart approved by both the FDA and Health Canada, with over 2,100 implants worldwide.
- The presentation at ISMCS 2025 demonstrates Picard Medical's commitment to advancing artificial heart technology.
- The fully implantable Emperor Total Artificial Heart signifies a major milestone in improving patient care and quality of life.
Picard Medical's presentation at ISMCS 2025 marks a significant step in the field of artificial heart technology, showcasing the innovative capabilities of the Emperor Total Artificial Heart.